Oxford Biomedica. 2005 to see 'Huge value creation' (Panmure Gordon)

TroVax is now close to/at PIII. A large slice of risk goes with approval to progress to PIII.
Crucially, TroVax has an excellent safety profile, efficacy is what we want and it all looks, from the data to date, and as the Exec have said again and again "encouraging". I think we will hear more on this in the NY.
Not much more one can say at this stage without stoking the market excessively and that just isn't Alan's style.

I think we getting very warm indeed. A little patient could go a very long way. I expect the trading in the days after xmas and into the early new year to be lively.